Vaccine Technology VII

An ECI Continuing Series

June 17-22, 2018
Fairmont Tremblant
Mont Tremblant, Quebec, Canada

Visitor Visa for Canada

Mont-Tremblant, Quebec, Canada

Call for Abstracts!                   Mark Your Calendar!

Request for Next Mailing

Please forward this link to colleagues who may be interested in the conference topic.

About This Conference

Building on the strong momentum established at the Vaccine I-VI meetings, our goal is to gather key leaders in the field to discuss progress and technological challenges facing vaccine development and manufacturing for global needs.

The meeting is organized by scientists from academia and industry in an intimate setting, and differentiates itself from commercial conferences by providing very high quality, cutting-edge scientific content.  This format is an outstanding opportunity for exchange of ideas among scientists from diverse backgrounds and with a representation from different regions of the world.  Many national and international organizations including The Bill and Melinda Gates Foundation as well as the vaccine industry have supported the previous meetings in this series.  We will frequently update our website to inform about confirmed speakers, workshops, abstract submission and registration information.

We are developing a strong scientific program, the draft of which will be available shortly.  Following the input from our Scientific Committee, we will organize keynote talks and technical sessions around current and upcoming major issues in vaccine technology.

We invite anyone interested in this conference and in the advancement of vaccine technologies to better deliver vaccines where needed to contact one of the co-chairs of the conference.

Amine Kamen
Charles Lutsch
Nathalie Garcon
Tarit Mukhopadhyay

Preliminary program – Oral Session Descriptions

Session I and Session II. Technological and Clinical Advances in Vaccinology

Chairs:  David Weiner, The Wistar Institute; USA; Udo Reichl, Max Planck Institute, Germany; Haru Pujar, Moderna Therapeutics, USA and Frank Baehner, CureVac AG, Germany

Our quickly growing understanding of both the immune system and the molecular biology of pathogens, pathogenesis and risk factors, all enable new strategies for prevention and treatment. New vectors, synthetic biology, and specific immune modulation are examples that will play prominent roles for the vaccinology of the 21st century. Bringing forward novel vaccines requires new antigen designs. For example, recombinant polypeptide vaccines and virus-like particle-based vaccines are licensed, and others are under development. Viral vector-based systems able to efficiently deliver nucleic acids into cells are being developed. Nucleic acids as pDNA vaccines can elicit antibody- and T cell-mediated protection and were demonstrated as safe in humans; meanwhile more efficient delivery of nucleic acids to improve cellular uptake and immunogenicity have been evaluated. Non-viral vector delivery of mRNA is being investigated for nucleic acid based vaccines. mRNA based vaccines can be produced rapidly, avoiding complexities associated with biological vaccine production, making them of choice for rapid responses to newly emerging pathogens. Some of these examples will be developed in this session dedicated to recent advances in vaccinology that promise to improve efficacy, safety and availability of “next generation” vaccines.

Session III and Session IV. Bioprocessing advances in vaccine manufacturing

Chairs:  Linda Lua, Queensland University, Australia; Francesc Godia, UAB, Spain; Richard Peluso, Merck and Co., USA; Manon Cox, Protein Sciences Corp.  USA

Production of efficacious and safe vaccines poses significant challenges in upstream and downstream processing. To reduce costs per dose and to cope with ever increasing demands, this session will focus on further steps towards process intensification to increase product yields, the establishment of platform technologies to speed up process development, advances in process analytics, and the use of disposables for campaign-based vaccine manufacturing. Simplification of industrialization, design with impact on footprint, cycle times, transport and storage of these thermostable compounds are expected. Whereas vaccine characterization applies to all phases of vaccine development, final release vaccine product and process consistency during manufacture. It encompasses all in vitro and in vivo assays to evaluate the biological, chemical and physical properties of a vaccine. In-depth characterization of vaccines provides an understanding on the function, potency and toxicity issues, and improves vaccine efficacy and safety. In addition, bio-analytical characterization plays a critical role in establishing comparability of the product produced with process, scale and site changes. This session will focus on testing strategies and case studies highlighting the pivotal role of analytical characterization in vaccine development, licensure, and post-licensure life cycle management. Examples from mature markets and developing countries will be highlighted.

Session V. Formulation, Analytics and Delivering Vaccines

Chairs:  Nathalie Garcon, Bioaster, France and Lakshmi Krishna, NRC, Canada,

This session deals with the different steps that need to be taken in order to bring a concept to the first clinical trial, from the definition of the vaccine form (formulation, route of administration) to the various steps that need to be taken before entering into humans. Each vaccine candidate is unique and will require specific approach, nonetheless a common path can be defined and followed to maximize the chances of reaching a fast go/no go decision. Those paths will be discussed, including from how to select the formulation and validate its choice, to discussing the new emerging delivery technologies that are being brought to the field of vaccines. Finally, this session will be concluded by a discussion among the speakers on the various avenues, their benefit and challenges.

Session VI. Capacity Building and Intervention Plan for Emerging and Re-emerging Infectious Diseases

Chairs:  Gary Kobinger, University Laval, Canada; Amadou A. Sall, Institute Pasteur Dakar, Senegal; Erin Sparrow, WHO, Geneva and CEPI representative (to be confirmed).

Infectious diseases remain one of the two leading causes of global mortality, keeling twice as much as cancers. It is estimated that hundreds of thousand pathogens remain to be discovered. Recent outbreaks including SARS, Ebola and Zika reveal major gaps in emergency response plans.

Recently, the Coalition for Epidemic Preparedness Innovations (CEPI) has been created building “on the global consensus that new and sustainable partnership models are needed to develop vaccines, diagnostics, and therapeutics to contain outbreaks of emerging and reemerging infectious diseases. Such partnerships should fill need for coordinated and proactive R&D and increased funding, stronger advanced development and manufacturing capabilities, regulatory innovations and harmonization of regulatory requirements” (Presentation Professor John Arne Røttingen, Interim CEO, CEPI to the WHO, 21 July 2017).

This session will provide a forum to experts to highlight case studies on the accelerated development of new vaccines against emerging pathogens, and share views on novel strategies in building capacities to improve preparedness against emerging and reemerging infectious diseases.

Session VII. Therapeutic Vaccines

Chairs:  Barry Buckland, BioLogicB, USA and Paula Alves, IBET, Portugal

The recognition of the key role of the immune system and of viruses in a wide range of diseases is increasing every day. In this session, new approaches for the development of therapeutic vaccines will be discussed. Of special interest is the identification of new immunological targets, therapies for oncology and addictions, the role of tolerization, and others.

Session VIII. One World, One Health

Chairs:  Andrew Potter, Vido-Intervac, Canada and Martha Yami, National Veterinary Institute (NVI); Ethiopia

The vast majority of emerging and re-emerging pathogens in humans is of animal origin. Most of this growing number of threats has its origin in wildlife, while humans are exposed either directly or through indirect domestic animal contacts. Effective and economical ways of protecting mankind from emerging diseases are best based on combatting zoonotic pathogens at the animal source. The “One Health” concept creates awareness of the major opportunities that exist to protect public health through policies aimed at controlling these pathogens at the level of their animal hosts, or more specifically, at the interface between humans, animals and their environments. Implementation of these policies places those who have regular contacts with domestic animals, like owners, handlers and veterinarians, in the front line together with those who regularly come into contact with wildlife and their environment. This session will highlight the importance of the integration between medical and veterinary disciplines within the One Health concept.


Workshop on Innovations in Global Health

Session Chairs:

  • David Robinson, Gates Foundation
  • Torey de Rozario, Gates Foundation
  • Tarit Mukhopadhyay, University College London

Vaccines have proven to be one the most successful public health initiative of the 20th century, averting millions of deaths and increasing life opportunities. However, their impact is yet to be fully felt globally due to issues of cost, distribution and manufacture. Innovations in vaccine technology are required to ensure that all person have access to vaccines, irrespective of wealth and that WHO targets for immunization are met.

Significant investment has been made into vaccine technologies by many partners to advance the Global Health agenda, including the Bill & Melinda Gates Foundation.  This workshop will highlight some of the research of the Foundation.

Specifically, this workshop will

  • Provide an overview of current research
  • Give examples of funded projects
  • Share best practises and advice for the application process
  • Outline future funding opportunities

Additional workshops are planned on:

  • Advanced upstream and downstream processing equipment to accelerate vaccine delivery
  • Advanced Process Analytical Technologies for robust manufacturing of vaccines
  • Synthetic biology for antigen design and production

Conference Organization

Conference Chairs:

Amine Kamen, McGill University,
Tarit Mukhopadhyay, University College London,
Nathalie Garcon, Bioaster,
Charles Lutsch, Sanofi Pasteur,

Poster Session Chairs:

Yvonne Thomassen, Intravac, Netherlands
Ernesto Chico, CIM, Cuba
Marc Aucoin, University of Waterloo, Canada

Scientific Committee:

Paula Alves (IBET)
Barry Buckland (BiologicsB)
Fred Cassel (PATH)
Leda Castilho (University of Rio de Janeiro)
Manon Cox (Protein Sciences)
Tony D’Amore (Sanofi-Pasteur)
Martin Friede (WHO)
Francesc Godia (Universitat Autònoma de Barcelona)
Florian Krammer (Icahn School of Medicine at Mount Sinai)
Gary Kobinger (Laval University)
Lakshmi Krishnan, (National Research Council of Canada)
Linda Lua (University of Queensland)
Laura Palomares (UNAM)
Richard Peluso (Merck)
Hari Pujar (Moderna Therapeutics)
Udo Reichl (Max Planck Institute)
David Robinson, (Bill and Melinda Gates Foundation)
Amadou Alpha Sall (Institut Pasteur de Dakar)
Brian Ward, (Medicago, Inc.)
Xuefeng Yu (CanSincoBiologics, Inc.)

Abstract Submission

Detailed session descriptions are available in the Preliminary Program above.  Please use these descriptions to pre-select up to two sessions where you believe your work fits best.

Abstracts (one page maximum) that include specific results and conclusions to allow a scientific assessment of the proposed oral presentation are invited.  Please prepared your abstract according to this template: docx or doc.

Abstracts must be submitted electronically using the template provided at: THIS LINK.

Oral abstract submission deadline:                January 28, 2018
Poster abstract submission deadline:            March 30, 2018

Abstracts of all presentations will be made available to conference participants prior to the start of the conference.

Note:  Only a limited number of oral presentation slots are available and thus all submissions for oral sessions will be considered for both oral and poster presentation.

Awards will be presented for the overall best poster and for the top three student posters.

Major Sponsors

Please click on the logo to visit the website.


18AA pfizer_rgb_pos

Sponsorship Levels

Please click HERE to view the opportunities for sponsorship.

Conference Venue

The Fairmont Tremblant Hotel, which made its official debut in February 1997, is located at the base of Mont Tremblant in the magnificent Laurentian region of Quebec.  The concept for Fairmont Tremblant hotel originated with the vision of a modern chateau situated in harmony with its natural surroundings and the colorful pedestrian village.  Architects and designers worked together to combine modern conveniences and a warm décor that reflected the mountain life.  The architects drew inspiration from 19th-century Quebec seigneury, whose grant Provencal-style residences dominated the merchant squares overlooking the outskirts of the village.

Embedded in the mountainside, the village of Mont Tremblant features French-inspired architecture that evokes the charm of old Quebec City, with pitched rooftops, corrugated shingles, old-fashioned chimneys and a U-shaped design opening onto a public square – a meeting place and public crossroads for the villagers.

18AA rustic fairmont_tremblantChasse-galerie sur le Mont Tremblant, a Quebec legend, tells the tale of a group of lumberjacks desperate to return home to their families after spending months in the Laurentian forests.  Visited one night by a mysterious stranger with a flying canoe, they boarded the craft and he expelled an enchanted command creating colorful sparks that propelled the canoe into the air.  As they passed over Mont Tremblant, they slowed their rhythm and lit a lantern to light up the night.  This inspired Fairmont Tremblant hotel’s rustic interior design.

Fairmont Tremblant, 3025 Chemin de la Chapelle, Mont Tremblant, Quebec, Canada

Canadian Visa Information

General Information about ECI

Engineering Conferences International (ECI) is a global engineering conferences program, originally established in 1962, that provides opportunities for the exploration of problems and issues of concern to engineers and scientists from many disciplines.

The format of the weeklong research conference provides morning and late afternoon or evening sessions in which major presentations are made. Available time is included during the afternoons for ad hoc meetings, informal discussions, and/or recreation. This format is designed to enhance rapport among participants and promote dialogue on the development of the meeting. We believe that the conferences have been instrumental in generating ideas and disseminating information to a greater extent than is possible through more conventional forums.

All participants are expected both to attend the entire conference and to contribute actively to the discussions. The recording of lectures and presentations is forbidden. As ECI conferences take place in an informal atmosphere, casual clothing is the usual attire.

Engineering Conferences International
32 Broadway, Suite 314, New York, NY 10004
T: 1-7212-514-6760 – F: 1-212-514-6030